Cost advantages of combination asthma therapy

Treatments in Respiratory Medicine

Volumn 3, Issue 3, 2004, Pages 133-137

  Campbell, Debbie A ^a   Robinson, Douglas S ^b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; PLACEBO; SALMETEROL;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CLINICAL STUDY; CLINICAL TRIAL; COST; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEVICE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRY POWDER; EVIDENCE BASED MEDICINE; HUMAN; INHALER; LOW DRUG DOSE; LUNG FUNCTION; METERED DOSE INHALER; MONOTHERAPY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-ANTAGONISTS; ASTHMA; DRUG COMBINATIONS; DRUG COSTS; HUMANS;

EID: 3442891504     PISSN: 11763450     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151829-200403030-00001     Document Type: Article

References (32)

1. National Heart Lung & Blood Institute. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): US Department of Health and Human Services, 1997: Publication no. 97-4051
2. British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London, et al. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52 Suppl. 1: S1-21
3. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroids in asthma patients. Lancet 1994; 344: 523-9
4. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-8
5. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbation of asthma. N Engl J Med 1997; 337: 1405-11
6. Bauman A, Mitchell CA, Henry RL, et al. Asthma morbidity in Australia: an epidemiological study. Med J Aust 1992; 156: 827-31
7. Burr ML, Limb ES, Andrae S, et al. Childhood asthma in four countries: a comparative survey. Int J Epidemiol 1994; 23: 341-7
8. Sears MR. Changing patterns in asthma morbidity and mortality. J Investig Allergol Clin Immunol 1995; 5: 66-72
9. Department of Health. Asthma: an epidemiological overview. London: HMSO, 1994
10. Barnes PJ, Jonsson B, Klim JB. The cost of asthma. Eur Respir J 1996; 9 (4): 636-42
11. Weiss KB, Gregen PJ, Ferrie PJ, et al. An economic evaluation of asthma in the United States. N Engl J Med 1992; 326: 862-6
12. Woo J, Cockram C. Cost estimates for chronic disease. Dis Manage Health Outcomes 2000; 1: 29-41
13. Smith DH, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156: 787-93
14. 2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-91
15. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guidelines on the management of asthma. Thorax 2003; 58 Suppl. 1: 1-94
16. Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000; 30 Suppl.: 2-5
17. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation for the treatment of asthma: a randomised, double-blind placebo-controlled trial. J Allergy Clin Immunol 2000; 105 (1): 1108-16
18. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50μg and fluticasone propionate 250μg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527-34
19. Jenkins C, Woolcock AJ, Saarelainen P, et al. Salmeterol/fluticasone propionate combination therapy 50/250μg twice daily is more effective than budesonide 800μg twice daily in treating moderate to severe asthma. Respir Med 2000; 94: 715-23
20. Aubier M, Pieter WR, Schlosser NJJ, et al. Salmeterol/fluticasone propinate (50/500μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93: 876-84
21. Bateman ED, Beasley R, Silins V, et al. Comparison of salmeterol/fluticasone propionate combination 50/100 bid delivered via metered dose inhaler or Diskus in patients with reversible airways obstruction [abstract]. Am J Respir Crit Care Med 2000; 161 (3): A197
22. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propinate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroids plus montelukast. J Allergy Clin Immunol 2000; 106: 1088-95
23. Reese PR, Mather DB, Mahajan P, et al. Combination of salmeterol/fluticasone propionate via a Diskus improves quality of life in asthma patients [abstract]. J Allergy Clin Immunol 1999; 103 (Pt 2): 69
24. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76-83
25. Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000; 60 (95): 1207-33
26. Seretide and Symbicort in asthma management. Drugs Ther Bull 2002; 40: 62-64
27. Johansson G, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100μg vs fluticasone propionate 100μg in adults and adolescents with asthma III: results. Pharmacoeconomics 1999; 16 Suppl. 2: 15-21
28. Palmqvist M, Price MJ, Sondhi S. Cost-effectiveness of salmeterol/fluticasone propionate 50/250μg vs fluticasone propionate 250μg in adults and adolescents with asthma IV: results. Pharmacoeconomics 1999; 16 Suppl. 2: 23-8
29. Pieters WR, Lundback B, Sondhi S, et al. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/500μg vs fluticasone propionate 500μg in patients with corticosteroid-dependent asthma V: results. Pharmacoeconomics 1999; 16 Suppl. 2: 29-34
30. Andersson FL, Buhl R, Mellem H, et al. Symbicort turbuhaler is a cost effective treatment in adult asthmatics [abstract]. J Allergy Clin Immunol 2002; 107: S245
31. Lundback B, Jenkins C, Price MJ, et al. Cost-effectiveness of salmeterol-fluticasone propionate combination product 50/250μg twice daily and budesonide 800μg twice daily in the treatment of adults and adolescents with asthma. Respir Med 2000; 94: 724-32
32. Andersson F, Stahl E, Barnes PJ, et al. Adding formoterol to budesonide in moderate asthma-health economic results from the FACET study. Respir Med 2001; 95: 505-12